WHO’s reaction to H1N1 influenced by drug companies, reports claim

Sunday, June 6, 2010

Reports suggest the World Health Organisation’s declaring a swine flu pandemic was an error driven by drug companies, and lead to unjustified fear. A year after the swine flu pandemic was declared, stocks are left unused and governments try to abandon contracts, pharmaceutical companies have profited at least £4.6billion from the sale of vaccines alone.

Reports by the British Medical Journal (BMJ), the Bureau of Investigative Journalism (BIJ) and the Council of Europe claim that The World Health Organisation reaction to H1N1 was influenced by pharmaceutical companies and that key scientists behind advice had financial ties with firms Roche and GlaxoSmithKline (GSK). These conflicts of interest have never been publicly disclosed by WHO, an apparent violation of its own rules.

The World Health Organisation issued H1N1 guidelines in 2004, recommending countries to stockpile millions of doses of antiviral medication. The advice prompted many countries around the world into buying up large stocks of Tamiflu, made by Roche, and Relenza manufactured by GSK.

A joint investigation with the BMJ and the BIJ, found that scientists involved in developing the WHO 2004 guidance had previously been paid by Roche or GSK for lecturing and consultancy work as well as being involved in research for the companies. “The WHO’s credibility has been badly damaged,” BMJ editor Fiona Godlee said in an editorial.

A report by the health committee of the Parliamentary Assembly of the Council of Europe, a 47-member human rights watchdog, found that the WHO’s reaction was influenced by drug companies that make H1N1 antiviral drugs and vaccines. It criticised WHO lack of transparency around the handling of the swine flu pandemic and says the public health guidelines by WHO, EU agencies and national governments led to a “waste of large sums of public money and unjustified scares and fears about the health risks faced by the European public.”

A spokesman for WHO said the drug industry did not influence its decisions on swine flu. Margaret Chan, the organisation’s director, had dismissed inquiries into its handling of the A/H1N1 pandemic as “conspiracy theories” earlier this year, she had said: “WHO anticipated close scrutiny of its decisions, but we did not anticipate that we would be accused, by some European politicians, of having declared a fake pandemic on the advice of experts with ties to the pharmaceutical industry and something personal to gain from increased industry profits.”

Yesterday, a 16-member “emergency committee” consisting of advisors from the World Health Organisation said that the H1N1 pandemic is not yet over. The WHO has refused to identify committee members, arguing that they must be shielded from industry pressure, so possible conflicts of interest with drug companies are unknown. The BMJ report also reveals that at least one expert on the “emergency committee” received payment during 2009 from GSK.

In related news, Reuters reported, Pfizer Inc, the world’s biggest drugmaker, is selling its swine vaccine business to Chinese Harbin Pharmaceutical Group for $50 million.